Apoptosis

Apoptosis is an autonomous, genetically controlled, orderly death of cells to maintain the stability of the internal environment. Unlike necrosis, apoptosis is not a passive process, but an active one, involving the activation, expression and regulation of a series of genes, and it is not a phenomenon of autologous damage under pathological conditions, but an active death process for better adaptation to the survival environment. Apoptosis is a fundamental biological phenomenon of cells and plays a necessary role in the removal of unwanted or abnormal cells in multicellular organisms. It plays an important role in the evolution of organisms, the stability of the internal environment, and the development of several systems. Apoptosis is not only a specific type of cell death, but also has important biological significance and complex molecular biological mechanisms.

Cat. No.	Product name
BP10001	KW-2449
BP10001	KW-2449 shows growth inhibitory activities against FLT3/ITD-, FLT3/D835Y-, and wt-FLT3/FL-expressing 32D cells, MOLM-13 and MV4;11 with GI50 values of 0.024, 0.046, 0.014, 0.024, and 0.011 μM, respectively. KW-2449 suppresses the phosphorylations of FLT3 (P-FLT3) and its downstream molecule phospho-STAT5 (P-STAT5) in MOLM-13 cells in a dose-dependent manner. KW-2449 increases the percentage of cells in the G1 phase of the cell cycle and reciprocally reduced the percentage of cells in the S phase, resulting in the increase of apoptotic cell population.
BP10066	Lacidipine
BP10066	Lacidipine is a lipophilic dihydropyridine calcium antagonist with an intrinsically slow onset of activity. Due to its long duration of action, lacidipine does not lead to reflex tachycardia. It displays specificity in the vascular smooth muscle, where it acts as an antihypertensive agent to dilate peripheral arterioles and reduce blood pressure.
BP10792	Lanraplenib
BP10792	Lanraplenib is a highly selective and orally active SYK inhibitor (IC50=9.5 nM) in development for the treatment of inflammatory diseases. Lanraplenib inhibits SYK activity in platelets via the glycoprotein VI (GPVI) receptor without prolonging bleeding time (BT) in monkeys or humans.
BP10793	Lanraplenib monosuccinate
BP10793	Lanraplenib monosuccinate inhibits SYK activity in platelets via the glycoprotein VI (GPVI) receptor without prolonging bleeding time (BT) in monkeys or humans. Lanraplenib monosuccinate is a highly selective and orally active SYK inhibitor (IC50=9.5 nM) in development for the treatment of inflammatory diseases.
BP10794	Lanraplenib succinate
BP10794	Lanraplenib succinate inhibits SYK activity in platelets via the glycoprotein VI (GPVI) receptor without prolonging bleeding time (BT) in monkeys or humans. Lanraplenib succinate is a highly selective and orally active SYK inhibitor (IC50=9.5 nM) in development for the treatment of inflammatory diseases.
BP10947	Lansiumarin C
BP10947	Lansiumarin C can decrease nitric oxide (NO) and tumor necrosis factor-α (TNF-α) production in lipopolysaccharide (LPS)-induced macrophages.
BP10252	Larotrectinib
BP10252	Larotrectinib is an orally administered inhibitor of the TRK kinase and is highly selective only for the TRK family of receptors(IC50s = 2-20 nM).
BP10395	L-Ascorbic acid sodium salt
BP10395	Sodium Ascorbate is a more bioavailable form of vitamin C that is an alternative to taking ascorbic acid as a supplement.
BP10943	LAT1-IN-1
BP10943	LAT1-IN-1 (BCH) significantly inhibit cellular uptake of amino acids and mTOR phosphorylation, which induces the suppression of cancer growth and apoptosis. is a selective and competitive inhibitor of large neutral amino acid transporter 1 (LAT1).
BP10023	Latifolin
BP10023	Latifolin is a strong DPPH-scavenger, it attenuates inflammatory responses by inhibiting NF-ÎºB activation via Nrf2-mediated heme oxygenase-1 expression. Latifolin displays potent anticarcinogenic phase II marker enzyme, quinone reductase (QR) inducing activity and high chemopreventive indices. Latifolin also shows antifungal activity against white- and brown-rot fungi.
BP10304	lavendustin A
BP10304	lavendustin A is a potent, cell-permeable inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase.
BP10305	lavendustin C
BP10305	Lavendustin C is a potent inhibitor of epidermal growth factor (EGF) receptor-associated tyrosine kinase.
BP10867	Lazertinib
BP10867	Lazertinib is an effective, highly mutant-selective and irreversible EGFR-TKI with IC50 values of 1.7 nM, 2 nM, 5 nM, 20.6 nM and 76 nM for Del19/T790M, L858R/T790M, Del19, L85R and Wild type EGFR respectively.
BP10908	LCB 03-0110 dihydrochloride
BP10908	LCB 03-0110 Dihydrochloride is a potent inhibitor of the c-Src kinase (IC50 = 1.3 nM) and tyrosine kinases in the BTK and SYK family, as well as in the DDR2 family. It inhibits LPS-induced activation of macrophages and TGF-β1-induced activation of fibroblasts in vitro, inhibits activation of macrophages and fibroblasts, and inhibits scarring in wound healing models.
BP10007	LCL161
BP10007	LCL161, a SMAC mimetic, effectivity binds to and inhibits multiple IAPs (i.e. XIAP, c-IAP).
BP10108	LDC000067
BP10108	LDC000067 is a highly specific and selective CDK9 inhibitor with an IC50 value of 44±10 nM.
BP10531	LDN-212854
BP10531	LDN-212854, a novel BMP inhibitor, exhibits greater selectivity for BMP versus the TGF-β type I receptors; possesses differences towards ALK2(IC50=1.3 nM) versus ALK1/3 compared to other inhibitors.
BP10694	LDN-214117
BP10694	LDN-214117 is a potent and selective ALK2 inhibitor.
BP10876	Lenalidomide
BP10876	Lenalidomide is a potent inhibitor of TNF-α that, at 10 μM, alters gene expression and cell viability in a range of cancer cell lines.
BP10787	Leucodin
BP10787	Leucodin shows high anti-hypercholesterolemic potential. Leucodin may have anti-allergic activity, it shows a potent inhibitory activity upon the beta-hexosaminidase release from RBL-2H3 cells in a dose-dependent manner with IC50 of 80 microM.